Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study, Published online: 12 September 2018; doi:10.1038/s41416-018-0244-1
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
https://ift.tt/2QocK2Y
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.